Additional studies in melanoma and breast cancer, which are strongly influenced by RhoA/C pathways, as well as identification of the properties of tumor subsets that might make them particularly responsive to this family of compounds will be important future directions. This evidence concerns the gene RHOA and breast carcinoma.